BPC-157: gastric pentadecapeptide research overview

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. The acronym stands for Body Protective Compound, and the compound consists of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of 1,419.53 Da. Unlike the GLP-1-class peptides, BPC-157 is not an approved pharmaceutical in any major jurisdiction and has no completed human efficacy trials; its evidence base consists entirely of preclinical studies conducted predominantly in rodent models, complemented by a limited number of pharmacokinetic and safety evaluations in rats and dogs. The breadth of tissue systems studied in animal models — gastrointestinal, musculoskeletal, neurological, and vascular — has generated considerable research interest, but the translation of preclinical findings to humans remains unestablished.

What is BPC-157?

BPC-157 is a synthetic 15-amino acid peptide fragment derived from a larger protein isolated from human gastric juice by researchers at the University of Zagreb, led by Predrag Sikiric, whose laboratory has produced the majority of published BPC-157 preclinical research over the past three decades. The full amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it is also identified by the alternative name PL-10 in older literature. Its molecular weight is 1,419.53 Da, substantially smaller than the GLP-1-class peptides. The synthetic compound does not occur naturally as a circulating peptide at measurable concentrations in human plasma; rather, it is isolated conceptually from gastric cytoprotective proteins, and the research-grade form is entirely synthetic.

BPC-157 has not been approved by the FDA, EMA, TGA, or any other major regulatory agency for any indication. As of May 2026, there are no completed phase 2 or phase 3 efficacy trials in humans for any indication. The compound is not a scheduled substance in the United States, Canada, or the United Kingdom, but is classified as a research-use compound in most jurisdictions. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of peptide hormones and related substances. The Australian Therapeutic Goods Administration has listed it as a Schedule 4 substance, restricting availability. A 2025 review in Pharmaceuticals (Józwiak et al., PMID 40005999) provides a comprehensive summary of the preclinical literature and patent landscape (see citations).

Mechanism of action

The mechanism of action of BPC-157 is not fully characterized and does not involve a single defined receptor with established binding kinetics in the manner of a GLP-1 agonist or other class-B GPCR ligand. Preclinical research has identified several overlapping molecular pathways that appear engaged in various tissue models. Prominent among these is activation of the vascular endothelial growth factor receptor 2 (VEGFR2) pathway via the Akt-eNOS (endothelial nitric oxide synthase) axis, which promotes angiogenesis — the formation of new blood vessels. This proangiogenic activity has been proposed as a central mechanism underlying the accelerated tissue repair observed in rodent wound, tendon, and intestinal injury models.

Additional mechanisms identified in preclinical literature include: upregulation of heme oxygenase-1 (HO-1) and other antioxidant enzymes via nitric oxide synthase interactions; modulation of ERK1/2 (extracellular signal-regulated kinase) signaling pathways involved in cell survival and proliferation; interaction with the growth hormone receptor and upregulation of GHR expression in injured tissue; and modulation of the dopaminergic and serotonergic systems in rodent central nervous system models. BPC-157 has also been shown in some rodent models to counteract the effects of various exogenous toxins on multiple organ systems, an effect described by Sikiric and colleagues as 'adaptive cytoprotection' or 'organoprotection' (see citations).

It should be noted that the multiplicity of proposed mechanisms reported across a large body of single-laboratory rodent studies has not been systematically replicated by independent groups in human cell lines or in vivo human models. The mechanistic picture presented in the literature should therefore be interpreted as a working hypothesis grounded in preclinical data, not as an established human pharmacological profile.

What the research shows

The BPC-157 research literature consists overwhelmingly of rodent (rat and mouse) experiments covering a wide array of injury and disease models. Published studies span gastrointestinal models (colitis, gastric ulcer, intestinal anastomosis), musculoskeletal models (tendon rupture, ligament transection, bone fracture), neurological models (spinal cord injury, traumatic brain injury, dopaminergic neurotoxicity), and cardiovascular models (ischemia-reperfusion injury, heart failure). Across these models, the pattern of findings generally suggests accelerated recovery of various histological and functional endpoints relative to vehicle controls. A 2025 literature and patent review (Józwiak et al., Pharmaceuticals, PMID 40005999) summarizes the breadth of this preclinical evidence (see citations).

A critical limitation of the BPC-157 evidence base is its concentration in a small number of research groups, limited independent replication, and the near-complete absence of human clinical trial data. A 2022 PMC review (Regeneration or Risk, PMC12446177) applying a systematic lens to the musculoskeletal healing literature concluded that while the preclinical findings are intriguing, they cannot yet support evidence-based conclusions for human application. A regulatory toxicology and pharmacology study published by Xu et al. in 2020 (PMID 32334036) evaluated safety and toxicology across multiple species and found no dose-limiting toxicity at evaluated doses in rats and dogs, which is the foundational safety data for the compound.

A pharmacokinetics and ADME study published in Frontiers in Pharmacology in 2022 (He et al., PMC9794587) characterized the absorption, distribution, metabolism, and excretion of BPC-157 following intravenous and intramuscular administration in rats and beagle dogs. This study provided the most detailed pharmacokinetic dataset in the published literature for this compound, reporting an elimination half-life of less than 30 minutes by the intravenous route in rats, with absolute bioavailability of approximately 14–19% following intramuscular injection in rats and 45–51% in dogs. The study found linear pharmacokinetics across the evaluated dose range and no evidence of dose-limiting toxicity (see citations).

Pharmacokinetics

BPC-157 has a systemic elimination half-life of less than 30 minutes by the intravenous and intramuscular routes in rodent plasma, based on the pharmacokinetic study published by He et al. in Frontiers in Pharmacology (2022; PMC9794587). This very short systemic half-life contrasts sharply with the peptides described elsewhere in Pepticker's learn section (semaglutide's ~7 days; tirzepatide's ~5.4 days; retatrutide's ~6 days). The half-life entry in the site's peptide catalog reads: '< 30 min systemic (IV/IM); local tissue effects persist longer.' The distinction between rapid systemic clearance and potentially sustained local tissue effects — which have been proposed to result from BPC-157's interaction with local growth factor pathways — is an active area of discussion in the preclinical literature.

Absolute bioavailability following subcutaneous and intramuscular routes has been characterized in rodent and canine models; human pharmacokinetic data are absent from the published literature as of May 2026. BPC-157 is a small peptide (15 amino acids, 1,419.53 Da) that undergoes proteolytic degradation by serum and tissue proteases; unlike the GLP-1 agonists, it has no albumin-binding acylation or protease-resistant backbone modifications to extend half-life. The pharmacokinetics of oral BPC-157 administration have been addressed in some preclinical studies, with results suggesting gastrointestinal stability relative to larger peptides, but bioavailability data in humans have not been published.

Common research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The published preclinical literature reports a dose range of approximately 10 mcg to 500 mcg per administration in rodent models, administered subcutaneously, intraperitoneally, or intramuscularly depending on the experimental design. The safety evaluation published by Xu et al. (Regul Toxicol Pharmacol, 2020; PMID 32334036) described BPC-157 as well tolerated across species with no dose-limiting toxicity observed at evaluated doses. The pharmacokinetics and ADME study by He et al. (Front Pharmacol, 2022; PMC9794587) employed intravenous and intramuscular routes in rats and dogs. A literature and patent review (Józwiak et al., Pharmaceuticals, 2025; PMID 40005999) provides broader context for dose ranges reported across the preclinical literature (see citations).

No human dose-ranging or dose-escalation clinical trials have been published for BPC-157 as of May 2026. All dose ranges in the literature are derived from animal studies; extrapolation to human dosing is not scientifically validated. Literature reports subcutaneous and intraperitoneal administration in rodent models; human pharmacokinetic data are limited to a single-dose safety study. Researchers should consult the primary literature directly and note that BPC-157 has no approved clinical use in any jurisdiction.

Storage and handling

Lyophilized BPC-157 is stored at −20 °C in a sealed, desiccant-protected vial. Once reconstituted, solutions should be maintained at 2–8 °C and used within 28 days. Reconstituted solutions should not be frozen. Exposure to direct light, prolonged ambient temperature, and repeated freeze-thaw cycles should be avoided to preserve peptide integrity. BPC-157 is a small peptide without protective backbone modifications, making it more susceptible to protease degradation in solution than the acylated GLP-1-class compounds; careful aseptic technique during reconstitution and storage is correspondingly important.

What BPC-157 is NOT

BPC-157 is sometimes discussed alongside other 'healing' peptides — most commonly TB-500 (thymosin beta-4 fragment), thymosin beta-4 itself, GHK-Cu, and Ipamorelin — but these are distinct compounds with different sequences, mechanisms, and evidence bases. BPC-157 is not TB-500: TB-500 is a synthetic fragment (residues 17–23) of thymosin beta-4, an actin-binding protein, with a molecular weight of 889.02 Da and a completely different amino acid sequence and mechanism of action. BPC-157 is not thymosin beta-4, which is a naturally occurring 43-amino acid peptide studied in phase 1 clinical trials for cardiac indications. BPC-157 is not GHK-Cu (glycine-histidine-lysine copper complex), a tripeptide with proposed collagen-stimulating effects. None of these compounds share BPC-157's amino acid sequence or its proposed gastric cytoprotective origin. Researchers should also note that BPC-157 is not approved for any human use and should not be confused with approved wound-healing agents or prescription peptides.

References

The citations below represent the primary peer-reviewed sources underlying the claims in this article. The most important primary literature includes the safety and toxicology evaluation by Xu et al. (PMID 32334036), the pharmacokinetics and ADME study by He et al. (PMC9794587), the 2025 multifunctionality and patent review by Józwiak et al. (PMID 40005999), and the 2022 musculoskeletal narrative review (PMC12446177). Readers should be aware that the BPC-157 literature is heavily concentrated in a single research group and that independent replication of key preclinical findings, and human clinical trial data, remain limited.